Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteomics profiling of research models for studying pancreatic ductal adenocarcinoma

ABSTRACT: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with a five-year survival rate of 10-15% due to late-stage diagnosis and limited efficacy of existing treatments. This study utilized proteomics-based system modelling to generate multimodal datasets from various research models, including PDAC cells, spheroids, organoids, and tissues derived from murine and human samples. Identical mass spectrometry-based proteomics was applied across the different models. Preparation and validation of the research models and the proteomics were described in detail. The assembly datasets we present here contribute to the data collection on PDAC, which will be useful for systems modeling, data mining, knowledge discovery in databases, and bioinformatics of individual models. Further data analysis may lead to generation of research hypotheses, predictions of targets for diagnosis and treatment and relationships between data variables.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Mus Musculus (mouse)

SUBMITTER: Animesh Sharma

LAB HEAD: Lars Hagen

PROVIDER: PXD057795 | Pride | 2024-12-18

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	20160505_Tumor_1.raw	Raw
	20160505_Tumor_2.raw	Raw
	20160505_Tumor_3.raw	Raw
	20160505_Tumor_4.raw	Raw
	20160505_Tumor_5.raw	Raw

Items per page:

1 - 5 of 7

Similar Datasets

Proteomics profiling of research models for studying pancreatic ductal adenocarcinoma

Project description:Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with a five-year survival rate of 10-15% due to late-stage diagnosis and limited efficacy of existing treatments. This study utilized proteomics-based system modelling to generate multimodal datasets from various research models, including PDAC cells, spheroids, organoids, and tissues derived from murine and human samples. Identical mass spectrometry-based proteomics was applied across the different models. Preparation and validation of the research models and the proteomics were described in detail. The assembly datasets we present here contribute to the data collection on PDAC, which will be useful for systems modeling, data mining, knowledge discovery in databases, and bioinformatics of individual models. Further data analysis may lead to generation of research hypotheses, predictions of targets for diagnosis and treatment and relationships between data variables.

2024-12-18 | PXD057798 | Pride

Proteomics profiling of research models for studying pancreatic ductal adenocarcinoma

2024-12-18 | PXD057793 | Pride

Proteomics profiling of research models for studying pancreatic ductal adenocarcinoma

Project description:Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with a five-year survival rate of 10-15% due to late-stage diagnosis and limited efficacy of existing treatments. This study utilized proteomics-based system modelling to generate multimodal datasets from various research models, including PDAC cells, spheroids, organoids, and tissues derived from murine and human samples. Identical mass spectrometry-based proteomics was applied across the different models. Preparation and validation of the research models and the proteomics were described in detail. The assembly datasets we present here may contribute to the data collection on PDAC, which will be useful for systems modeling, data mining, knowledge discovery in databases, and bioinformatics of individual models. Further data analysis may lead to generation of research hypotheses, predictions of targets for diagnosis and treatment and relationships between data variables. bridging the gap between preclinical research and clinical trials, thus enhancing the possibilities for discovering early diagnostic biomarkers and effective therapeutic targets.

2024-12-18 | PXD057928 | Pride

Proteomics profiling of research models for studying pancreatic ductal adenocarcinoma

2024-12-18 | PXD057829 | Pride

Proteomics profiling of research models for studying pancreatic ductal adenocarcinoma

2024-12-18 | PXD057888 | Pride

Proteomics profiling of research models for studying pancreatic ductal adenocarcinoma

Project description:Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with a five-year survival rate of 10-15% due to late-stage diagnosis and limited efficacy of existing treatments. This study utilized proteomics-based system modelling to generate multimodal datasets from various research models, including PDAC cells, spheroids, organoids, and tissues derived from murine and human samples. Identical mass spectrometry-based proteomics was applied across the different models. Preparation and validation of the research models and the proteomics were described in detail. The assembly datasets we present here may contribute to the data collection on PDAC, which will be useful for systems modeling, data mining, knowledge discovery in databases, and bioinformatics of individual models. Further data analysis may lead to generation of research hypotheses, predictions of targets for diagnosis and treatment and relationships between data variables. bridging the gap between preclinical research and clinical trials, thus enhancing the possibilities for discovering early diagnostic biomarkers and effective therapeutic targets.

2024-12-18 | PXD057804 | Pride

Profiling of pancreatic adenocarcinoma using artificial intelligence-based integration of multi-omic and computational pathology features

Project description:Contemporary analyses focused on a limited number of clinical and molecular features have been unable to accurately predict clinical outcomes in pancreatic ductal adenocarcinoma (PDAC). Here we describe a novel, conceptual approach and use it to analyze clinical, computational pathology, and molecular (DNA, RNA, protein, and lipid) analyte data from 74 patients with resectable PDAC. Multiple, independent, machine learning models were developed and tested on curated singleand multi-omic feature/analyte panels to determine their ability to predict clinical outcomes in patients. The multi-omic models predicted recurrence with an accuracy and positive predictive value (PPV) of 0.90, 0.91, and survival of 0.85, 0.87, respectively, outperforming every singleomic model. In predicting survival, we defined a parsimonious model with only 589 multi-omic analytes that had an accuracy and PPV of 0.85. Our approach enables discovery of parsimonious biomarker panels with similar predictive performance to that of larger and resource consuming panels and thereby has a significant potential to democratize precision cancer medicine worldwide.

2024-01-23 | PXD037038 | Pride

Microarray expression profile analysis of circular RNAs in human pancreatic ductal adenocarcinoma

Project description:To explore the potential involvement of circular RNAs (circRNAs) in pancreatic ductal adenocarcinoma (PDAC) oncogenesis, we conducted circRNA profiling in six pairs of human PDAC and adjacent normal tissue by microarray. Our results showed that clusters of circRNAs were aberrantly expressed in PDAC compared with normal samples, and provided potential targets for future treatment of PDAC and novel insights into PDAC biology. Analyze circular RNA expression in pancreatic ductal adenocarcinoma (PDAC) by microarray platform.

2015-11-20 | E-GEOD-69362 | biostudies-arrayexpress

Small RNA-Sequencing of PDAC tissues and control samples.

Project description:FASTQ Sequencing files of 5 healthy pancreas tissues and 6 pancreatic ductal adenocarcinoma (PDAC) tissues. Analysis of data is presented in the manuscript: Next generation sequencing reveals novel differentially regulated mRNAs, lncRNAs, miRNAs, sdRNAs and a piRNA in pancreatic cancer in BMC Molecular Cancer.

2015-05-15 | E-MTAB-3494 | biostudies-arrayexpress

Proteomics profiling of research models for studying pancreatic ductal adenocarcinoma

2024-12-18 | PXD057607 | Pride